{"url_path":"/sec/revbw/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Information.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-251784-index.html","accession_number":"0001193125-26-251784","cik":"0001810560","ticker":"REVB","issuer_name":"REVELATION BIOSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-251784-index.html","primary_entity_key":"0001810560","primary_entity_name":"REVELATION BIOSCIENCES, INC."},"word_count":140,"has_tables":true,"body_markdown":"## Item 8.01 Other Information.\n\nOn June 1, 2026, Revelation Biosciences, Inc. (the “Company”) prepared and released an updated corporate presentation made available to the public. The corporate presentation can be found on the Company’s website. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.\n\nThe information in this Item 8.01 and in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing."}